News & Updates

Neoadjuvant treatment with the PARP* inhibitor olaparib yielded encouraging outcomes in patients with BRCA-mutated ovarian cancer, with all participants completing two cycles of therapy followed by surgery in the NOW trial presented at SGO 2023.

The subcutaneous infliximab formulation CT-P13 appears beneficial in the maintenance treatment of patients with moderately to severely active ulcerative colitis (UC), with data from the phase III study LIBERTY-UC showing that the drug outperforms placebo in multiple endpoints.

Communication between physicians and patients with systemic lupus erythematosus (SLE) leaves a lot to be desired, with a recent study suggesting that rheumatologists must beef up communication to match the health literacy (HL) of their patients. Doing so may foster trust and improve self-management and outcomes in SLE.

A robust association exists between increased natriuresis and successful decongestion with acetazolamide in patients with acute decompensated heart failure (ADHF), suggests a study.

In the post hoc analysis of data from the phase III LIBERTY ASTHMA VOYAGE study, the monoclonal antibody dupilumab reduced exacerbations and improved lung function in children aged between 6 and 11 years with moderate-to-severe asthma and baseline blood eosinophil count of ≥500 cells/μL.

Supplementation with vitamin D falls short of reducing psoriasis severity for individuals with 25-hydroxyvitamin D (25[OH]D) levels of <24 ng/mL, as reported in a study.